Other SSAO inhibitor Programs

Pharmaxis is currently investigating two additional opportunities in its SSAO inhibitor program:



SSAO/MAOB – neuro inflammation

SSAO/VAP-1 and MAOB enzymes are involved in Alzheimer's Disease, multiple sclerosis and cardiometabolic diseases. Pharmaxis has developed a dual SSAO/MAOB inhibitor that is currently being tested in pre clinical models of neuro inflammation.

SSAO/MPO – respiratory

SSAO/VAP-1 is upregulated in models of inflammatory lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease and COPD patients also have increased SSAO/VAP-1 in the lung. Pharmaxis has developed SSAO inhibitors that are effective in pre clinical models and has the potential to enhance efficacy through enhanced chemistry to target the additional myloperoxidase (MPO) pathway.